翰森制药(03692.HK)治疗卵巢癌药物获国家药监局纳入突破性治疗药物

阿斯达克财经
02 May

翰森制药(03692.HK) 公布,旗下B7-H4靶向抗体-药物偶联物注射用HS-20089,获中国国家药品监督管理局批准纳入突破性治疗药物,拟定适应症为用于铂耐药复发上皮性卵巢癌、输卵管癌或原发性腹膜癌患者。
据介绍,上述药物正于中国开展用于治疗卵巢癌以及其他妇科肿瘤的多项临床研究,其中最高研究阶段为临床III期。(js/w)

(港股报价延迟最少十五分钟。沽空资料截至 2025-04-30 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10